CBP-174 is a peripherally acting histamine 3 receptor (H3R) antagonist for oral administration to treat chronic pruritus associated with skin inflammation.
There are four types of histamine receptors, and most common antihistamines block the H1 receptor, which can lead to undesirable central nervous system side effects. CBP-174 was designed not to penetrate the blood brain barrier and has been well-tolerated in multiple preclinical studies.
Pruritus due to atopic dermatitis
Chronic inflammatory pruritus (itch) is a hallmark of atopic dermatitis (AD) and is one of the most difficult AD symptoms to manage.1 In some cases, the sense of itch may be so intense that patients scratch themselves until they bleed.1 Pruritus also has negative impacts on quality of life for patients with AD.1 Currently available anti-inflammatory agents may require many days or weeks of continuous treatment to provide relief to patients with pruritus associated with AD.1 We believe novel therapies that rapidly, safety and effectively reduce chronic pruritus will be important for improving health and quality of life outcomes for patients with pruritus due to AD.
Mechanism of Action
Promising Preclinical Data
In a preclinical model of histamine-induced pruritus in mice, CBP-174 at an oral dose of 0.1 mg/kg led to significant reductions in scratching. We observed that CBP-174 had a strong anti-itch effect in mice with a rapid onset of action, within the first 30 minutes of dosing. Administration of CBP-174 orally was well-tolerated with no clinical signs of toxicity in a 28-day multiple-dose study of up to 5 mg/kg in rats.
CBP-174 is expected to commence a Phase 1 trial in 2021.